Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
NCT03920267
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
261
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
BMS-986165
Sponsor
Bristol-Myers Squibb